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Chronic obstructive pulmonary disease (COPD) is the 
third leading cause of morbidity and mortality glo bally, 
contributing to a substantial use of resources.[1] According 
to World Health Organization estimates, 65 million people 
have moderate to severe COPD.[2] The condition is also 
recognised as a systemic disease with extrapulmonary manifestations, 
such as peripheral muscle dysfunction, malnutrition and depression, 
which further contribute to disability, poor quality of life, exacerbations 
and mortality. Optimum management requires non-pharmacological 
interventions combined with pharmacological treatment. However, the 
former is often neglected and not widely used in daily practice, with the 
focus mainly on the latter. 
Non-pharmacological management options for COPD include 
smoking cessation, pulmonary rehabilitation, pneumococcus and 
influenza vaccinations, non-invasive positive pressure ventilation 
(NPPV), long-term oxygen therapy (LTOT), surgery and broncho-
scopic lung volume reduction. 
Smoking cessation remains the only proven intervention to slow the 
decline of lung function and should be prioritised in the management 
of COPD patients. A gradual decline in forced expiratory volume 
in 1 second (FEV1) is a normal part of ageing; however, decline is 
accelerated in patients with COPD, with greater decline in the early 
stages of COPD (Global Initiative for Chronic Obstructive Lung 
Disease (GOLD I and II)),[3] emphasising the importance of early 
smoking cessation interventions. 
Pulmonary rehabilitation has been shown to be the most effective 
non-pharmacological intervention for improving health status and 
quality of life in COPD patients and addresses aspects of the disease 
not sufficiently covered by medical therapy, including peripheral 
muscle dysfunction, cachexia, social isolation and psychological 
issues. 
Pneumoccocal and influenza vaccines may reduce infectious 
exacerbations – the most common cause of acute decompensation. 
NPPV is beneficial during acute exacerbations, reducing the need for 
intubation, length of stay in the intensive care unit, and mortality rate 
during hospitalisation. Long-term supplemental oxygen improves 
the mortality rate and quality of life in patients with severe resting 
hypoxaemia. Surgical options in COPD include lung volume 
reduction surgery (LVRS), bullectomy and lung transplantation. 
Bronchoscopic lung volume reduction is still being studied and is 
an emerging therapy in the management of COPD, not yet approved 
for use in the clinical setting. This article elaborates on the non-
pharmacological interventions available for the management of 
COPD, which complement appropriate pharmacological therapy.
Smoking cessation
As smoking is the most important modifiable risk factor for COPD, 
quitting smoking is critical to reduce the occurrence and progression 
of the disease. Findings from landmark studies such as the Lung 
Health Study from the USA[4] show that long-term smoking cessation 
is associated with a reduction in the rate of FEV1 decline and survival. 
Smoking cessation not only benefits the lung (reduction in lung 
cancer, reduced lung function loss), but also reduces the risk of 
cardiovascular disease and other smoking-related conditions. 
Effective smoking cessation requires a combination of pharmaco-
logical therapy and behavioural support and counselling. The South 
African Thoracic Society clinical practice guideline is a useful 
resource to assist clinicians.[5] 
Pharmacological options include nicotine replacement therapies, 
such as nicotine gum, patches, oral inhalers and sprays, varenicline 
(Champix) and bupropion (Zyban). All healthcare professionals 
should give smoking cessation advice to every smoker at every point 
of contact. The 5 major steps of a smoking intervention may be 
summarised as 5 As:
•  Ask: enquire about tobacco use during every patient contact (both 
current and past patterns of smoking).
•  Alert: urge all smokers to quit and provide information on the 
benefits of quitting.
• Assess: determine willingness to make an attempt to quit.
•  Assist: help the patient to quit by referral for further counselling 
and pharmacotherapy.
• Arrange: schedule a follow-up visit.
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Pulmonary rehabilitation
Advanced COPD is associated with systemic inflammation, and 
increased circulating levels of cytokines and oxidative stress 
promote muscle loss, peripheral muscle dysfunction and cachexia. 
Deconditioning is associated with a shift from type I to type II fibres, 
which are less-endurance fibres. Furthermore, progressive dyspnoea 
associated with moderate to severe disease leads to limitation of 
physical activity, resulting in disuse atrophy and a vicious cycle of 
progressive deconditioning. Other factors that possibly play a role 
in peripheral muscle dysfunction include corticosteroid use, hypoxia 
and malnutrition.[6] 
Pulmonary rehabilitation (PR) is a broad therapeutic concept 
defined as a multidisciplinary intervention comprising exercise 
training, education and psychological support aimed at improving 
quality of life and reducing disability in patients with chronic 
respiratory disease.[6] PR addresses extrapulmonary problems in 
COPD not covered by pharmacological therapies, such as exercise 
deconditioning, social isolation, anxiety, depression, muscle wasting 
and weight loss.
A comprehensive PR programme has various components and 
may include patient assessment, exercise training, smoking cessation, 
nutrition, education and psychosocial support. Multidisciplinary 
teams are involved, including healthcare professionals such as 
physicians, nurses, physiotherapists, psychologists, dieticians and 
social workers. Current guidelines suggest a minimum length 
of an effective rehabilitation programme (6 weeks), with longer 
programmes showing better results.[7] The optimal duration has 
not yet been determined. In the absence of formally structured PR 
programmes, home-based exercise programmes may be encouraged, 
e.g. leisure walking is associated with increased endurance.[8]
The benefits of PR are summarised in Table 1. Indications include 
patients with chronic respiratory impairment who, despite optimal 
medical management, have dyspnoea, reduced exercise tolerance 
or restriction of activities.[7] PR is also effective in reducing rates of 
hospitalisation and mortality after an acute exacerbation.[9] 
Exercise training
Exercise training involves aerobic lower-extremity endurance 
training. Baseline exercise tolerance can be assessed by formal 
cardiopulmonary testing using treadmill or ergometry bicycling. 
Simpler methods such as the 6-minute walk test may also be 
used. Guidelines suggest a training frequency varying from 
daily to weekly, with duration ranging from 10 to 45 minutes 
and intensity from 50% of peak oxygen consumption to the 
maximum tolerated.[7,8] Interval training is another option for 
patients unable to tolerate continuous endurance training and 
consists of high-intensity exercise alternating with periods of rest 
or lower-intensity exercise. Resistance training provides a greater 
increase in muscle mass and strength than endurance training and 
causes less dyspnoea, making it an option for patients with severe 
dyspnoea and those who are hospitalised. Endurance and strength 
training also complement each other.[7] 
Transcutaneous neuromuscular electrical stimulation (NMES) of 
leg muscles is a technique involving involuntary muscle contraction 
induced by electrical stimulation with training of selected muscle 
groups.[10] NMES improves leg muscle strength and reduces dyspnoea 
in stable patients with severe COPD and poor baseline exercise 
tolerance.[10] It also has added benefits and can be continued during 
COPD exacerbations.[11]
Some programmes include upper-extremity training, as everyday 
activities require the hands. However, studies have shown no benefit 
for dyspnoea and quality of life. Another non-conventional form of 
exercise includes ventilatory muscle training (studies done mostly 
in inspiratory muscle training), which has shown mixed results in 
clinical trials. 
Nutritional support
Malnutrition and cachexia are common in COPD patients. Low body 
mass index (BMI) and fat free mass index (FFMI) are predictors 
of poor prognosis and associated with a higher mortality (BMI 
forms part of the body mass index, airflow  obstruction,  dyspnoea 
and exercise capacity (BODE) index for COPD mortality prediction). 
Nutritional supplementation should be considered in individuals 
with a BMI <21. No beneficial effects have been seen in trials 
investigating the use of testosterone, appetite stimulants and creatine 
in COPD patients with a low BMI.
Education
Patient education is an important part of PR and includes information 
about COPD, smoking cessation, appropriate use and administration 
of pharmacological therapies, decision-making during exacerbations, 
and advance directives, recognising and treating complications and 
end-of-life issues. The benefits include better adherence to treatment 
and fewer hospital and emergency visits.
Influenza and pneumococcal 
vaccinations
Acute exacerbations are a major cause of morbidity and mortality 
worldwide. Most acute exacerbations are triggered by community-
acquired respiratory infections (viral or bacterial). Although clinical 
trial data are limited and not conclusive, vaccinations can prevent 
some of the infections that cause exacerbations. The current GOLD 
guidelines[3] recommend that all patients with COPD receive influenza 
and pnemoccocal (pneumococcal polysaccharide vaccine) vaccines, 
depending on availability. Small cohort studies have suggested 
additive benefits of administering both influenza and pneumoccocal 
vaccines in reducing hospitalisation and mortality.[12,13] 
Non-invasive positive pressure 
ventilation 
NPPV improves the outcome in severe exacerbations of COPD 
complicated by hypercapnia and respiratory acidosis. Evidence regarding 
long-term NPPV in COPD patients with hypercapnia is contradictory 
Table 1. Benefits of Pulmonary Rehabilitation in COPD
• Improves exercise capacity (Evidence A).
• Reduces the perceived intensity of breathlessness (Evidence A).
• Improves health-related quality of life (Evidence A). 
• Reduces the number of hospitalizations and days in the hospital 
(Evidence A).
• Reduces anxiety and depression associated with COPD (Evidence A).
•  Strength and endurance training of the upper limbs improves 
 arm function (Evidence B).
• Benefits extend well beyond the immediate period of training (Evidence B).
• Improves survival (Evidence B).
• Respiratory muscle training can be beneficial, especially when 
combined with general exercise training (Evidence C).
• Improves recovery after hospitalization for an exacerbation (Evidence A).
• Enhances the effect of long-acting bronchodilators (Evidence B).
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and there are no recommendations on its use.[7] An exception is the 
subsets of patients with COPD and coexisting obstructive sleep apnoea 
or obesity hypoventilation, where clear benefits are seen.
Long-term oxygen therapy 
The Nocturnal Oxygen Therapy Trial (NOTT) and Medical Research 
Council (MRC) trials demonstrated that LTOT (>15 hours/day) is 
associated with improved survival in patients with severe resting 
hypoxaemia, with no benefits seen in moderate hypoxaemia PO2 >8 kPa 
(60 mmHg). Indications for LTOT include the following:[7]
• PaO2 = 7.3 kPa or SaO2 ≤88%, with or without hypercapnia.
• PaO2 between 7.3 kPa (55 mmHg) and 8 kPa (60 mmHg or SaO2 88%), 
if there is evidence of pulmonary arterial hypertension, peripheral 
oedema suggestive of congestive heart failure or polycythaemia.
Surgery 
Surgical options for COPD include LVRS, bullectomy and lung 
transplantation.
Lung volume reduction surgery 
LVRS involves the surgical reduction of lung volume, with multiple 
excisions improving elastic recoil and reducing hyperinflation. It is 
also thought to improve the mechanical function of the diaphragm 
and intercostal muscles by returning the diaphragm to a more 
normally curved and lengthened configuration. It is beneficial in 
selected COPD patients with upper-lobe emphysema. The National 
Emphysema Treatment Trial (NETT)[14] demonstrated survival 
benefits in patients with upper-lobe emphysema and low exercise 
capacity, with no benefits and increased mortality seen in FEV1 <20% 
predicted, diffusing capacity of the lungs for carbon monoxide <20 
and non-upper-lobe emphysema on computed tomography scanning. 
It is, however, associated with significant morbidity postoperatively.
Bullectomy
Bullectomy involves removal of one or more large bullae that do 
not contribute to gas exchange, decompressing the adjacent lung 
parenchyma and improving ventilation. Indications include dyspnoea 
from giant bullae occupying >30% of the hemithorax (especially >50%), 
spontaneous pneumothorax, haemoptysis and repeated infections. 
Lung transplantation
Lung transplantation is done infrequently in resource-limited countries 
such as South Africa (7 lung transplantations done in 2013). COPD is 
the most common indication for a single lung transplant. Indications 
for placing a patient with COPD on the transplant list would include 
a BODE index ≥7, FEV1 <15 - 20% of predicted, ≥3 exacerbations in 
the last year, 1 severe exacerbation with hypercapnic respiratory failure 
and moderate to severe pulmonary hypertension.[15]
Conclusion 
Non-pharmacological interventions are complementary to pharma-
cological therapies in COPD. Smoking cessation is the only proven 
method to prevent decline in lung function and therefore must 
be addressed during all patient visits, with the implementation 
of an appropriate individually tailored pulmonary rehabilitation 
programme. Yearly influenza vaccination will reduce the risk of 
influenza with subsequent COPD exacerbations or pneumonia. 
Pneumococcal vaccination shows great promise and should be used 
where available. Keeping one’s patients healthy and strong by means 
of nutrition and moderate exercise will contribute to their sense of 
wellbeing and improve their respiratory health.
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